Data di Pubblicazione:
2022
Citazione:
Antibiotics for lung disease and cancer / A. Arcadu, M. Silani, F. Amati, A. Gramegna, F. Blasi, S. Aliberti - In: Lung Diseases and Cancer / [a cura di] M. A. Martinez-Garcia, M. Gaga, K. M. Fong. - Prima edizione. - Sheffield (UK) : European Respiratory Society, 2022. - ISBN 978-1-84984-154-2. - pp. 299-305 [10.1183/2312508X.10020821]
Abstract:
Lung cancer patients frequently present with respiratory tract infections. The presence of multidrug-resistant pathogens is associated with unfavourable outcomes, including the persistence of bacteraemia, metastatic infection and higher case-fatality rates. Antibiotics may increase the risk of cancer development, and affect cancer treatment efficacy and toxicity by inducing changes in the microbiota. Further research is needed to clarify the role of antibiotics in the dysregulation between the microbiota and the immune system, and is crucial for lung cancer prevention and treatment. Monitoring gut microbiota composition and administering protective commensal bacteria could potentially improve cancer treatment response and tolerability, leading to better oncological outcomes.
Tipologia IRIS:
03 - Contributo in volume
Elenco autori:
A. Arcadu, M. Silani, F. Amati, A. Gramegna, F. Blasi, S. Aliberti
Link alla scheda completa:
Titolo del libro:
Lung Diseases and Cancer